ライフサイエンスコーパス: tau

1 inal fluid concentration of amyloid-beta and tau.

2 uish between patients with FTLD-TDP and FTLD-tau.

3 of CSF core biomarkers Abeta42, P-tau and T-tau.

4 t 2 (R2) and proline-rich region 2 (PRR2) of tau.

5 forms of the microtubule-associated protein tau.

6 ecies of soluble, oligomeric, seed-competent tau.

7 AD may have distinct biochemical features of tau.

8 ecks on microglial reactivity to amyloid and tau.

9 of the timing of disease-related changes in tau.

10 n the ACD enhances chaperone activity toward tau.

11 in the microtubule-binding repeat region of tau.

12 cell surface binding and internalization of tau.

13 ts with "neurotypical" levels of amyloid and tau.

14 o target individuals at risk of accumulating tau.

15 e (Kendall tau = 0.29), noncalcified plaque (tau = 0.16), and CAC (tau = 0.33).

16 etween risk and carotid wall volume (Kendall tau = 0.29), noncalcified plaque (tau = 0.16), and CAC (

17 , noncalcified plaque (tau = 0.16), and CAC (tau = 0.33).

18 Blue excitation light induced a rapid (tau ~0.8 s), PLC-dependent decrease in fluorescence, rep

19 different recovery parameters ( r(1) = 0.09, tau(1) = 5.3, r(2) = 0.46, tau(2) = 10.1, r(3) = 0.86, t

20 rs ( r(1) = 0.09, tau(1) = 5.3, r(2) = 0.46, tau(2) = 10.1, r(3) = 0.86, tau(3) = 9.8, r(4) = 0.89, t

21 % CI 1.81-2.93; heterogeneity test Q=326.21; tau(2)=0.0042; I(2)=71.40%; p<0.0001).

22 62% (2.25-7.65; heterogeneity test Q=527.33; tau(2)=0.0384; I(2)=95.05%; p<0.0001), with a significan

23 ypical low dissociation rate (residence time tau = 205 min).

24 We have reported previously that a region of tau (297-391), referred to as dGAE, assembles spontaneou

25 .3, r(2) = 0.46, tau(2) = 10.1, r(3) = 0.86, tau(3) = 9.8, r(4) = 0.89, tau(4) = 2.7, r(5) = 0.93, ta

26 0.1, r(3) = 0.86, tau(3) = 9.8, r(4) = 0.89, tau(4) = 2.7, r(5) = 0.93, tau(5) = 1.2).

27 ature decay time of the Omega Fe-C5' bond of tau ~ 5-6 s, likely shortened by enzymatic activation as

28 9.8, r(4) = 0.89, tau(4) = 2.7, r(5) = 0.93, tau(5) = 1.2).

29 e time-specific associations were notable: t-tau 8 to 16 years, and Nf-L and GFAP 4 to 8 years prior

30 Soluble oligomers of aggregated tau accompany the accumulation of insoluble amyloid fibr

31 The topography of longitudinal tau accumulation and atrophy differed across phenotypes,

32 ledge about conditions affecting the rate of tau accumulation could guide the development of therapie

33 fered across phenotypes, with key regions of tau accumulation in the frontal and temporal lobes for a

34 significant independent predictors of higher tau accumulation rates.

35 strategies aim to prevent the intracellular tau accumulation.

36 HDAC6 reversibly regulates tau acetylation, but its role in tauopathy progression r

37 ow nanomolar affinity, and inhibits cellular Tau aggregate propagation similarly to standard porcine

38 The spread of tau aggregates (neurofibrillary tangles) across the cere

39 Misfolded tau aggregates are able to spread the pathology from cel

40 haracteristics of the different strains that tau aggregates can adopt.

41 x Tau isoforms as well as Sarkosyl-resistant Tau aggregates extracted from cell cultures and human AD

42 showing that LSD1 localizes to pathological tau aggregates in Alzheimer's disease cases, and that it

43 injection of pathologic tau led to increased tau aggregates in mice in which p.Asp395Gly VCP mice was

44 Line 66 mice express intracellular tau aggregates in multiple brain regions and exhibit sen

45 The accumulation of amyloid Tau aggregates is implicated in Alzheimer's disease (AD)

46 sp70 machinery to recognize a broad range of Tau aggregates.

47 trate that hAPP overexpression aggravates EC-Tau aggregation and accelerates pathological tau spread

48 erstanding of factors associated with faster tau aggregation and spread.

49 harmaceutical compounds with the HEK293 cell tau aggregation assay, we obtained only a low number of

50 cleaving enzyme-1 (BACE-1), and Abeta42 and tau aggregation inhibition).

51 ries have demonstrated both beta-amyloid and tau aggregation, including neurofibrillary tangles, with

52 -tau cytotoxicity apparently via enhancing p-tau aggregation.

53 LLPS was shown to facilitate tau amyloid aggregation in certain cases, while being in

54 ther the ATN framework or the phosphorylated-tau/amyloid-beta1-42 ratio.

55 ExNef further potentiated phosphorylation of Tau and activation of inflammatory pathways.

56 a focus on two major pathological proteins: tau and alpha-synuclein.

57 Blood p-tau181 can predict tau and amyloid beta pathologies, differentiate Alzheime

58 TDP-43, tau and amyloid-beta have all been linked to hippocampal

59 ns on the aggregation and internalization of tau and aSyn.

60 The interaction between tau and LRP1 is mediated by lysine residues in the micro

61 NT1 tau and NfL were measured in plasma from prospectively f

62 ss activation of Fyn kinase and its targets, tau and NMDA-NR2B, and decreased Rho kinase signaling ch

63 drial calcium homeostasis is also related to tau and other risk factors in AD, although an ongoing ch

64 DH6 levels were positively correlated with t-tau and p-tau in the total sample as well as in APOE eps

65 baseline cerebrospinal fluid phosphorylated tau and subthreshold Abeta were associated with increase

66 with that of CSF core biomarkers Abeta42, P-tau and T-tau.

67 oinflammation relates to the localization of tau and TDP-43 pathology, and to the heterogeneity of cl

68 isease; standard cut-offs for phosphorylated tau and total tau may thus result in misclassifications

69 ylated microtubule-associated protein tau (p-tau) and extracellular plaques primarily comprising amyl

70 ive diseases including prion protein (PrPC), tau, and alpha-synuclein.

71 assessed relationships among CBF/sPDGFRbeta, tau, and cognition.

72 isease pathogenesis, but longitudinal Abeta, tau, and neurodegeneration (A/T/N) measurements in the s

73 w we examine, in the context of the amyloid, tau, and neurodegeneration framework, the available evid

74 tingtin (mHTT), alpha-synuclein (alpha-syn), tau, and others, raising the possibility that autophagy

75 ing ours, have reported that neurons secrete tau, and several therapeutic strategies aim to prevent t

76 otein phosphorylated at threonine 181, total tau, and the ratio of phosphorylated tau to amyloid-beta

77 nt, it is unclear whether and how TDP-43 and tau are associated with early or late hippocampal atroph

78 onstrate that multiple zinc-binding sites on tau are involved in the LLPS-promoting effect and provid

79 The pathological actions of phosphorylated tau are mediated by surrounding neuronal proteins; howev

80 rimary age-related tauopathy, ageing-related tau astrogliopathy and multiple subtypes of frontotempor

81 onal deep red (lambda(max) = 621 nm, = 0.32, tau(av) = 366 ns) thermally activated delayed fluorescen

82 efully, to the development and refinement of tau-based therapeutics.

83 Development of tau-based therapies for Alzheimer's disease requires an

84 lfation (3-O-S) of HS significantly enhances tau binding.

85 We show that tau binds both to a well-known binding groove within the

86 me is strongly concordant with the burden of tau (Braak score, P = 1.0 x 10(-5)), Abeta (CERAD score,

87 gh flortaucipir correlated with quantitative tau burden across regions.

88 explored autophagy as a mechanism to reduce tau burden in human neurons and, from a small-molecule s

89 nowledge of the authors the association with tau burden is unknown.

90 HDAC6 not only deacetylates tau but also suppresses tau hyperphosphorylation within

91 viduals who had SCD or MCI revealed that NT1 tau, but not tau measured using Quanterix or Roche assay

92 Interestingly, in vitro Tau can be induced to form fibrillar filaments by oxidat

93 xperimental studies(3,4) have suggested that tau can spread in a prion-like manner, by passing to nai

94 te that, in the presence of crowding agents, tau can undergo liquid-liquid phase separation (LLPS), f

95 term for the top one metre of soil (DeltaC(s,tau)) can be diagnosed from projections made with the CM

96 (18)F-fluorodeoxyglucose PET and CSF p-tau changes occurred later in the fourth decade of life,

97 dy suggests that caspase-2 (Casp2)-catalyzed tau cleavage at aspartate 314 mediates synaptic dysfunct

98 CSF tau concentrations at the time of the CM episode may ide

99 One such prominent gap is the mechanism of Tau condensation and fibrillization.

100 the formation of non-filamentous pathogenic tau conformations.

101 ault mode network (DMN) displays amyloid and tau-containing neurofibrillary tangle (NFT) pathology du

102 t, a subset of benzodiazepines exacerbated p-tau cytotoxicity apparently via enhancing p-tau aggregat

103 and synapse degeneration through an array of tau-dependent and independent mechanisms.

104 I, proNGF correlated with cerebral Abeta and tau deposition and to cognitive performance.

105 (AT) memory network appears to drive higher tau deposition in AT than in the posterior-medial (PM) m

106 nned with (18)F-AV-1451 tau PET to determine tau deposition in the brain and with MRI to determine th

107 cterized by the presence of amyloid-beta and tau deposition in the brain, hippocampal atrophy and inc

108 used for (18)F-PI-2620 PET quantification of tau deposits, avoiding arterial blood sampling.

109 With 20 kDa PEG, we demonstrate label-free tau detection in a wide concentration range with detecti

110 illary degeneration in part owing to reduced tau disaggregation, raising the possibility that VCP may

111 Clinical trials with anti-tau drugs will need to target individuals at risk of acc

112 ologically or pathologically associated with tau (e.g. RNA binding protein HNRNPA1).

113 Tau enriched in the synapse of line 66 mice, therefore,

114 P-tau expression was transiently elevated in HSV-1-infecte

115 me 1, and both total and hyperphosphorylated tau expression, correlated with impaired preoperative ex

116 terestingly without changes to the levels of tau expression, phosphorylation or aggregation.

117 between disease-related mutations, LLPS, and tau fibrillation.

118 Cryo-EM and mass spectrometry of tau filaments from CBD reveal that this conformer is hea

119 gests that conformational characteristics of tau filaments, along with regional vulnerability to tau

120 nction remains constant in CH but decreases (tau for SERCA-mediated Ca(2+) removal changed from 6.3 t

121 ant role in clearing accumulated amyloid and tau from neurons.

122 ogy of PSP is unknown, mutations in the MAPT/tau gene and exposure to environmental toxins can increa

123 However, although the propagation of tau has been extensively studied, the underlying cellula

124 Aggregation of tau has been implicated in neurodegeneration, cellular t

125 elationship between the sleep-wake cycle and tau have not been previously discussed in other reviews

126 trates that this rare 3-O-sulfation enhances tau-HS binding and likely the transcellular spread of ta

127 However, the structural determinants for tau-HS interaction are not well understood.

128 ot only deacetylates tau but also suppresses tau hyperphosphorylation within the microtubule-binding

129 luding reduced Abeta accumulation as well as tau hyperphosphorylation, and improve synaptic dysfuncti

130 to reach a consensus on normal and abnormal tau imaging values that can be universally implemented i

131 o establish tau positivity (T+) for multiple tau-imaging tracers in order to reach a consensus on nor

132 upport a synergistic role for both Abeta and tau in driving neuronal dysfunction seen in AD.

133 acute sleep deprivation increases levels of tau in mouse brain interstitial fluid (ISF) and human ce

134 s pathological structures that are formed by tau in neurodegenerative diseases.

135 were positively correlated with t-tau and p-tau in the total sample as well as in APOE epsilon4 stra

136 ive conclusions about the biological role of tau in these models.

137 loid (Abeta) and hyper-phosphorylated tau (p-tau) in Vero and glioblastoma cells.

138 vealed a strong role for hAPP/Abeta, but not tau, in the emergence of EC neuronal hyperactivity and i

139 of frontotemporal lobar degeneration (FTLD) tau inclusions has been unsuccessful.

140 es of frontotemporal lobar degeneration with tau inclusions.

141 Others (p-tau205 and t-tau) increase with atrophy and hypometabolism closer to

142 y implicated the histone demethylase LSD1 in tau-induced neurodegeneration by showing that LSD1 local

143 standing of the proteins that phosphorylated tau interacts with in Alzheimer's disease is surprisingl

144 ically by aggregation of hyperphosphorylated tau into neurofibrillary tangles (NFTs).

145 Accumulation of phosphorylated tau is a key pathological feature of Alzheimer's disease

146 Tau is a microtubule-associated protein that plays a maj

147 Plasma NT1 tau is a specific marker of AD, which is elevated early

148 lel to its intracellular accumulation in AD, tau is also released in the extracellular space, as reve

149 One viewpoint is that positively charged Tau is condensed by cytosolic polyanions.

150 the combination of pathological amyloid and tau is detrimental to cognitive decline in preclinical A

151 bcellular fractionation confirmed that human tau is highly enriched in insoluble cytosolic and synapt

152 The amyloid fibrillar form of the protein Tau is involved in a number of neurodegenerative disease

153 In Alzheimer's disease (AD), human Tau is phosphorylated at S199 (hTau-S199-P) by the prote

154 Tau is predominantly an intraneuronal protein but is als

155 ptosomal fractions, whereas endogenous mouse tau is virtually absent from synapses.

156 Our results demonstrate that all Tau isoform fibrils exhibit paired-helical-filament-like

157 easing proportions of the slowly aggregating tau isoform gradually lowers the concentration of the is

158 d recombinant fibrils assembled from all six Tau isoforms as well as Sarkosyl-resistant Tau aggregate

159 ments of which are made of three-repeat (3R) tau isoforms) and from Alzheimer's disease and chronic t

160 Differential tau isoforms, expression levels, promoters, and disrupti

161 a (FTD) as well as in the wild-type mice and tau knock-out and P301L tau mouse models.

162 Consequently, tau knockdown in mouse islet beta-cells facilitates micr

163 However, tau knockout could modestly promote the formation of alp

164 regulates the secretion of truncated mutant tau lacking MTBR and this process is dependent on the ly

165 , intracerebral microinjection of pathologic tau led to increased tau aggregates in mice in which p.A

166 Flortaucipir correlated with tau lesion score in red nucleus and midbrain tegmentum a

167 reatments increased total and phosphorylated tau levels in both cell types, implicating Cr and Ni exp

168 targeting vascular health, amyloid-beta, and tau levels may more effectively preserve cognitive funct

169 We observed no tau LLPS-promoting effect for any other divalent transit

170 In line with these effects on tau, LM11A-31 inhibited excess activation of Fyn kinase

171 0.27; P = .005) amyloid beta load and global tau load (rho = 0.31; P = .001).

172 Full kinetic modeling to quantify tau load was investigated.

173 ulin (GRN) or microtubule-associated protein tau (MAPT) and their first-degree biological family memb

174 se findings suggest that phase separation of tau may facilitate the formation of non-filamentous path

175 rd cut-offs for phosphorylated tau and total tau may thus result in misclassifications for non-amnest

176 ad SCD or MCI revealed that NT1 tau, but not tau measured using Quanterix or Roche assays, is elevate

177 tions between plasma NfL and PET amyloid and tau measures were independently assessed in two cohorts:

178 biting LSD1 via sequestration contributes to tau-mediated neurodegeneration.

179 and linked to neurodegenerative diseases is tau (microtubule-associated protein tau), which can caus

180 licated in the initiation and progression of tau misfolding and aggregation are largely unclear.

181 diverse prokaryotic and eukaryotic cells in tau misfolding and aggregation.

182 ly toxic due to their strong ability to seed tau misfolding and propagate the pathology seen across d

183 igh-strain rate deformation alone can induce tau mislocalization to dendritic spines and synaptic def

184 e wild-type mice and tau knock-out and P301L tau mouse models.

185 I(+/+) mice, expressing the pathogenic human Tau mutant (hTau-P301L), the hTau S199 phosphorylation w

186 P8 reduced the intracellular accumulation of tau mutants linked to frontotemporal dementia with parki

187 r uptake in these regions compared to young, tau-negative controls.

188 verall, binding across both tau-positive and tau-negative non-Alzheimer disorders did not reliably co

189 mulation of amyloid-beta (Abeta) plaques and tau neurofibrillary tangles in the brain.

190 h the development of behavioral deficits and tau neuropathology.

191 Serum t-tau, Nf-L, and GFAP predict the development of sporadic

192 concentrations of an N-terminal fragment of tau (NT1) in a large, well-characterized cohort of clini

193 ent (scFv) inhibited seeding by IL15-induced tau oligomers and pathological extracts from donors with

194 Recent evidence has demonstrated that tau oligomers, small and soluble prefibrillar aggregates

195 ptide 42 (amyloid-beta42) and phosphorylated tau on the patterns of functional connectomics involved

196 ly than an intrinsically disordered protein (Tau) on MTs.

197 er other similar proteopathic seeds, such as tau or alpha-synuclein, can also be transferred iatrogen

198 hosphorylated microtubule-associated protein tau (p-tau) and extracellular plaques primarily comprisi

199 eta-amyloid (Abeta) and hyper-phosphorylated tau (p-tau) in Vero and glioblastoma cells.

200 t the use of recombinant hyperphosphorylated tau (p-tau) to identify potential tauopathy therapeutics

201 lex inverted haplotype of the MAPT (encoding tau) Parkinson's disease risk locus, identifying putativ

202 n vivo positron emission tomography (PET) of tau pathologies in Alzheimer's disease (AD), although se

203 opathologies and compared this to a range of tau pathologies, including Alzheimer's disease, primary

204 studied how baseline assessments of in vivo tau pathology (measured by 18F-AV-1451 PET), neuroinflam

205 tween clinical severity and both subcortical tau pathology (R = 0.667, p = 0.003) and neuroinflammati

206 and initiate a deleterious cascade involving tau pathology and neurodegeneration.

207 Roles of Abeta42/40 ratio on tau pathology are also confirmed with APP transmembrane

208 luate the ability of (18)F-PI-2620 to detect tau pathology in AD patients using PET imaging, as well

209 hip between amyloid-beta (Abeta) species and tau pathology in Alzheimer's disease (AD) is not fully u

210 tatus represents a new strategy to alleviate tau pathology in FTLD and related tauopathies.

211 ossible to study the temporal progression of tau pathology in vivo.

212 rment, but is not related to amyloid-beta or tau pathology measured in cerebrospinal fluid or by posi

213 tain, however, how it relates to amyloid and tau pathology or neurodegeneration across the Alzheimer'

214 ntified latent variables relating amyloid or tau pathology with combinations of personality traits, n

215 aments, along with regional vulnerability to tau pathology, account for the distinct histopathologica

216 c for AD, correlates with cerebral Abeta and tau pathology, and predicts future cognitive decline.

217 hows close correspondence with the extent of tau pathology, as assessed by Braak tangle stage.

218 differential vulnerability of brain areas to tau pathology, its cell-to-cell transmission, and charac

219 cent data regarding biomarkers for Abeta and tau pathology, neurodegeneration, synaptic dysfunction,

220 changes in the microglial transcriptome and tau pathology.

221 did not reliably correspond with post-mortem tau pathology.

222 ell types, implicating Cr and Ni exposure in tau pathology.

223 at Abeta plaque deposition precedes cortical tau pathology.

224 nvolvement of glymphatic CSF-ISF exchange in tau pathology.

225 y; 4 women) were scanned with (18)F-AV-1451 tau PET to determine tau deposition in the brain and wit

226 sess the safety and tolerability of this new tau PET tracer.

227 Tau PET was a significant mediator CBF/sPDGFRbeta-MoCA r

228 d cohort where the correlation with 18F-GTP1 tau PET was evaluated (Alzheimer's disease = 38, control

229 d 60 matching controls also underwent AV1451 tau PET.

230 inal fluid (CSF) P-tau217, CSF P-tau181, and tau-PET (AUC range, 0.90-0.99; P > .15).

231 lzheimer's disease are different for MRI and tau-PET and may differ across phenotypes, particularly f

232 Using immunohistochemistry, we performed tau phenotyping of CTE neuropathologies and compared thi

233 We examined whether plasma tau phosphorylated at residue 181 (pTau181) could differ

234 ing was performed to measure levels of total-Tau, phosphorylated-Tau (pTau), amyloid precursor protei

235 ealed that NUB1 also mediated a reduction in tau phosphorylation and aggregation following proteasome

236 conflicting results regarding the extent of Tau phosphorylation in cells.

237 reduction in Abeta levels and deposition and tau phosphorylation.

238 Overall, binding across both tau-positive and tau-negative non-Alzheimer disorders di

239 he study, with four of these animals showing tau-positive tangles and neuropil threads.

240 d potential alternatives on how to establish tau positivity (T+) for multiple tau-imaging tracers in

241 ted with CSF P-tau181 and predicted positive Tau positron emission tomography (PET) scans (area under

242 rmative features for AD classification using tau positron emission tomography (PET) scans.

243 Imaging measures of AT(N) (amyloid and tau positron emission tomography [PET]) structural magne

244 Furthermore, the recent advent of tau positron emission tomography and novel fluid-based b

245 n assay that mimics molecular recognition of tau pre-mRNA by a U1 small nuclear ribonucleoprotein (sn

246 , and to rescue disease-relevant splicing of tau pre-mRNA in a variety of cellular systems, including

247 The compounds are shown to directly target tau pre-mRNA in cells, via chemical cross-linking and is

248 These data support the idea that tau preferentially spreads to specific cortical regions,

249 ular propagation of pathology is mediated by Tau prions, which are ordered protein assemblies that fa

250 We studied tau propagation in the left hemispheric syntactic networ

251 sleep deprivation accelerates the spread of tau protein aggregates in neural networks.

252 omposed of hyperphosphorylated and misfolded tau protein are a pathological hallmark of Alzheimer's d

253 Filaments made up of different isoforms of tau protein are associated with a variety of neurodegene

254 tauopathy-a class of disorders in which the tau protein forms insoluble inclusions in the brain-that

255 Although abnormally folded tau protein has been found to self-propagate from neuron

256 Tau protein in cerebrospinal fluid (CSF) is a central an

257 aggregation of the intrinsically disordered tau protein into highly ordered beta-sheet-rich fibrils

258 Tau protein is subjected to proteolytic processing into

259 iously overlooked role in the propagation of tau protein misfolding and AD pathogenesis, providing a

260 concentrations of amyloid-beta1-42 peptide, tau protein phosphorylated at threonine 181, total tau,

261 Further, tau protein transference via the extracellular space, th

262 groups of the 3D-Au-PAMAM-p-ABA-SPCE, where tau protein was sandwiched with a secondary antibody lab

263 Abnormal changes of neuronal Tau protein, such as phosphorylation and aggregation, ar

264 el to test the possible interactions between tau proteins and amyloid-beta and study the resulting co

265 d by the accumulation of aberrantly modified tau proteins.

266 nding and likely the transcellular spread of tau, providing a novel target for disease-modifying trea

267 measure levels of total-Tau, phosphorylated-Tau (pTau), amyloid precursor protein (APP), GFAP, Iba1,

268 Building on recent reports that tau readily undergoes liquid-liquid phase separation (LL

269 (2020) identify a therapeutic role for tau reduction in downregulating this pathway and amelior

270 Increased tau secretion by VAMP8 was also observed in murine hippo

271 These findings suggest that normal cellular Tau shows a remarkably high extent of phosphorylation, w

272 Tau aggregation and accelerates pathological tau spread into the hippocampus.

273 llmarks: amyloid plaques (A), phosphorylated tau (T), and accompanying neurodegeneration (N).

274 sses neuroimaging biomarkers of amyloid (A), tau (T), and neurodegeneration (N) for potential racial

275 ns comprehensive information on amyloid (A), tau (T), and neurodegeneration (N) status as required by

276 correlated with both the amyloid burden and tau tangle density, and no other associations of brain i

277 ponse may precede insoluble Abeta plaque and tau tangle formation.

278 Plasma P-tau217 levels correlated with tau tangles in participants with (Spearman rho = 0.64; P

279 ases, are found in association with neurons, tau tangles, and beta-amyloid in specimens from the brai

280 he patterns in the substrate that depends on tau/tau(D) and can be much larger than the cell size.

281 odel reveal that the fidelity decreases with tau/tau(D), a result that is reproduced by a continuum r

282 , total tau, and the ratio of phosphorylated tau to amyloid-beta1-42.

283 ge of assays that measured direct binding of Tau to glycosaminoglycans and inhibition of Tau uptake a

284 ution of amyloid precursor protein (APP) and Tau to lipid rafts and increased the abundance of these

285 se of recombinant hyperphosphorylated tau (p-tau) to identify potential tauopathy therapeutics and ri

286 ggest that therapies downstream of Abeta and tau together are more suitable to combat AD than therapi

287 than worms harboring either the Abeta1-42 or tau transgene alone and interestingly without changes to

288 Further, these changes occurred in the Abeta;tau transgenic animals at greater levels than worms harb

289 Yet the mechanism of glial tau transmission is unknown.

290 Tau tubulin kinase 2 (TTBK2) is a critical regulator of

291 Tau tubulin kinase 2 (TTBK2) is a key player in the cili

292 lemented to describe variability in baseline tau uptake and rates of accumulation and baseline grey m

293 Tau to glycosaminoglycans and inhibition of Tau uptake and seeding in cells.

294 Knockdown of LRP1 significantly reduced tau uptake in H4 neuroglioma cells and in induced plurip

295 Biased agonism was assessed by comparing k(tau) values for arrestin recruitment with those for Gq s

296 conditions, where total concentration of all tau variants in the condensed phase is constant.

297 Tau was measured using Quanterix and Roche assays in bas

298 eases is tau (microtubule-associated protein tau), which can cause frontotemporal dementia and parkin

299 on the aggregation and spreading of aSyn and tau will be important for the development of future ther

300 SN7-13 does not inhibit coagulation, binds Tau with low nanomolar affinity, and inhibits cellular T